Form 4: Tenaya Therapeutics CEO Faraz Ali Receives Stock Options and Restricted Stock Units
SEC Form 4
CEO Faraz Ali received 505,000 stock options and 85,000 restricted stock units in Tenaya Therapeutics, Inc.
Summary
- Faraz Ali, CEO of Tenaya Therapeutics, Inc., received 85,000 shares of common stock in the form of restricted stock units on February 23, 2024.
- These restricted stock units were granted under the company's 2021 Equity Incentive Plan.
- The restricted stock units will vest in installments, starting with 1/8th on August 15, 2024, and then 1/8th every six months until fully vested.
- Following the transaction, Ali directly owns 198,079 shares, including 178,750 shares from previously granted restricted stock units.
- Ali also received options to purchase 505,000 shares of common stock at an exercise price of $5.22 on February 23, 2024.
- These options, also granted under the 2021 Equity Incentive Plan, will vest monthly over four years.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The equity grants are a standard practice and align the CEO's interests with shareholders. The vesting schedules promote long-term commitment.
Positives
- The grant of stock options and restricted stock units aligns the CEO's interests with those of the shareholders.
- The vesting schedules encourage long-term commitment from the CEO.
Future Outlook
The vesting schedules for both the restricted stock units and stock options suggest a long-term commitment from the CEO to the company's success.
Industry Context
Equity grants are a common practice in the biotech industry to incentivize and retain key executives. The size and vesting schedule of these grants are typical for a company of Tenaya Therapeutics' size and stage.
Comparison to Industry Standards
- Stock option grants to CEOs in the biotech industry typically range from 1% to 5% of outstanding shares, depending on the company's size and performance.
- Restricted stock unit grants are also common, often vesting over a 3-4 year period to align executive compensation with long-term shareholder value creation.
- Comparable companies like CRISPR Therapeutics and Editas Medicine also utilize equity grants as a key component of executive compensation packages.
Stakeholder Impact
- Shareholders: Aligns CEO's interests with long-term company performance.
- Employees: Reinforces the company's commitment to incentivizing leadership.
Key Dates
| Date | Description |
|---|---|
| 02/23/2024 | Date of transaction: Grant of restricted stock units and stock options. |
| 03/23/2024 | First vesting date for stock options (one month anniversary of grant date). |
| 08/15/2024 | First vesting date for restricted stock units (1/8th of total). |
| 02/22/2034 | Expiration date for stock options. |
| 02/27/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.